Sierra Oncology, Inc. (SRRA) has seen an increase of 64.15% in the premarket after the company announced a financial update to Support the Commercialization of Momelotinib. However, the last trading session concluded at $15.51 with a decrease of 8.06%.
Commercialization of Momelotinib – What’s up?
On 25th January 2022, SRRA reported that it has signed a term loan agreement with Oxford Finance. This will help in funding the commercialization and eventual launch of momelotinib. As the company extends work toward an NDA submission and eventual approval of momelotinib, a solid cash position, along with the term loan agreement with Oxford, gives them a lot of financial flexibility.
Phase 3 MOMENTUM study Data Revealed!
SRRA reported phase 3 Momentum Study data on 25th January 2022. The company is ecstatic to see data confirming momelotinib’s potential as a treatment option for anemic or at-risk myelofibrosis patients. At the time of diagnosis, half of all myelofibrosis patients have anemia, and almost all become anemic over time. Given that the majority of presently authorized medications are myelosuppressive, it’s exciting to think that these patients may have such a powerful therapy choice very soon.
Topline Data Timing – What’s happening?
SRRA announced on 18th January 2022 that the company is planning to release the topline data sooner than expected. Hopefully, SRRA will release the stats by the end of January 2022. Everyone is excited to know about the facts and figures related to the Phase 3 study because it costs a lot of team effort. Not only this but the team is dedicated to getting this potential drug to myelofibrosis patients, especially those with anemia, as soon as possible.
About SRRA
SRRA is a late-stage biopharmaceutical company that is dedicated to developing and commercializing targeted cancer therapies for patients suffering from rare tumors. Moreover, they apply comprehensive scientific expertise to develop molecules that treat the disease’s fundamental cause. To better understand the limitations of current treatments the team uses an evidence-based approach. Last but not the least, they are collaborating to help patients transform their potential into reality.
